Evidence map›Paper›PMID 26446611›Full record

ArticleCurrent infectious disease reports2015

The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia.

Alexandra McFarlane, Wendy Sligl

Abstract read
PubMed Publisher
In one paragraph

Article in Current infectious disease reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Detection of Macrolide-ResistantThe Malaysian journal of medical sciences : MJMS · 2024
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alexandra McFarlaneDivision of Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, 1-124 Clinical Sciences Building, 8440 112 Street, Edmonton, AB, T6G 2B7, Canada. amcfarla@ualberta.ca.
Wendy SliglDivisions of Critical Care Medicine and Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, 2-124 Clinical Sciences Building, 8440 112 Street, Edmonton, AB, T6G 2B7, Canada. wsligl@ualberta.ca.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrolide antimicrobials are commonly prescribed, specifically for the treatment of respiratory tract infections. Although still effective, the development of widespread macrolide resistance has limited their use. Aside from their antimicrobial effects, macrolides are also known to possess immune-modulatory properties which may confer a survival benefit in both acute and chronic inflammatory states. This review discusses the efficacy, potential mechanisms, and adverse effects of macrolide therapy specifically in community-acquired pneumonia in outpatients, hospitalized ward patients, and those requiring intensive care unit admission. Challenges for ongoing research in this field are discussed and treatment recommendations offered.

Indexed as

Community-acquired pneumoniaMacrolide antimicrobialsMacrolide-based regimensRespiratory tract infections

Identifiers

PMID26446611
OpenAlexW1854486753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.